search
Back to results

Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE (ESOGUARDBE1)

Primary Purpose

Barrett Esophagus, Esophageal Adenocarcinoma, Barretts Esophagus With Dysplasia

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
EsoGuard
Sponsored by
Lucid Diagnostics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Barrett Esophagus

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  1. Men aged 50 years old and older
  2. ≥5 years either of

    • GERD symptoms,
    • GERD treated with proton pump inhibitor (PPI) therapy (whether symptom control is achieved or not), or,
    • any combination of treated and untreated periods, as long the cumulative total is at least 5 years
  3. No solid foods eaten for at least 2 hours prior to EsoCheck procedure
  4. One or more of the following risk factors:

    1. Caucasian race
    2. Current or past history of cigarette smoking
    3. BMI of at least 30 kg/m2
    4. First-degree relative with BE or EAC

      -

Exclusion Criteria:

  1. History of prior EGD procedure
  2. Inability to provide written informed consent
  3. On anti-coagulant drug(s) that cannot be temporarily discontinued
  4. Known history of esophageal varices or esophageal stricture
  5. Any contraindication, as deemed in Investigator's medical judgment, to undergoing the EsoCheck procedure, undergoing the EGD procedure, and/or having biopsies taken, including but not limited to due to comorbidities such as coagulopathy or a known history of esophageal diverticula, esophageal fistula and/or esophageal ulceration
  6. History of difficulty swallowing (dysphagia) or painful swallowing (odynophagia), including swallowing pills
  7. Oropharyngeal tumor
  8. History of esophageal or gastric surgery, with exception of uncomplicated surgical fundoplication procedure
  9. History of myocardial infarction or cerebrovascular accident within past 6 months
  10. History of esophageal motility disorder
  11. Currently implanted Linx device

Sites / Locations

  • Lucid Investigative Site
  • Lucid Investigative Site
  • Lucid Investigative Site
  • Lucid Investigative Site
  • Lucid Investigative Site
  • Lucid Investigative Site
  • Lucid Investigative Site
  • Lucid Investigative Site
  • Lucid Investigative Site
  • Lucid Investigative Site
  • Lucid Investigative Site
  • Lucid Investigative Site
  • Lucid Investigative Site
  • Lucid Investigative Site
  • Lucid Investigative Site
  • Lucid Investigative Site
  • Lucid Investigative Site
  • Lucid Investigative Site
  • Lucid Investigative Site
  • Lucid Investigative Site
  • Lucid Investigative Site
  • Lucid Investigative Site
  • Lucid Investigative Site
  • Lucid Investigative Site
  • Lucid Investigative Site
  • Lucid Investigative Site
  • Lucid Investigative Site

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

EsoCheck vs. EGD with or without biopsies

Arm Description

All subjects will undergo both the EsoCheck (non-invasive esophageal cell sample collection) followed by EGD (with or without biopsies)

Outcomes

Primary Outcome Measures

Primary Efficacy
The sensitivity and specificity of EsoGuard for the diagnosis of BE on samples collected using EsoCheck, wherein the definitive diagnosis of BE is made by concomitant EGD and biopsy.

Secondary Outcome Measures

Secondary Efficacy
Negative predictive value (NPV) and positive predictive value (PPV), calculated for the observed prevalence and over a range of prevalences from 1 to 15%.

Full Information

First Posted
February 26, 2020
Last Updated
January 23, 2023
Sponsor
Lucid Diagnostics, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04293458
Brief Title
Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE
Acronym
ESOGUARDBE1
Official Title
A Multicenter, Single-Arm Study of the Efficacy of EsoGuard(TM) on Samples Collected Using EsoCheck(TM) Versus Esophagogastroduodenoscopy for the Diagnosis of Barrett's Esophagus in an At-Risk Screening Population
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Completed
Study Start Date
February 28, 2020 (Actual)
Primary Completion Date
August 22, 2022 (Actual)
Study Completion Date
August 22, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lucid Diagnostics, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The study will assess the performance of the combined system, i.e., the use of the EsoGuard assay on cells collected using the EsoCheck 510(k) cleared device, to detect Barrett's Esophagus, with and without dysplasia, and/or Esophageal Adenocarcinoma, in individuals deemed to be at high risk for these conditions (i.e., screening) per ACG guidelines.
Detailed Description
This is a multicenter, single-arm study designed to assess the operating characteristics of the EsoGuard diagnostic assay performed on distal esophageal mucosal cells collected using the EsoCheck cell collection device, compared to the gold standard, for the screening of BE with and without dysplasia and for esophageal adenocarcinoma (EAC), in patients at high risk for BE and for whom a screening EGD is indicated according to ACG-established criteria.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Barrett Esophagus, Esophageal Adenocarcinoma, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Multicenter, Single Arm
Masking
None (Open Label)
Allocation
N/A
Enrollment
145 (Actual)

8. Arms, Groups, and Interventions

Arm Title
EsoCheck vs. EGD with or without biopsies
Arm Type
Experimental
Arm Description
All subjects will undergo both the EsoCheck (non-invasive esophageal cell sample collection) followed by EGD (with or without biopsies)
Intervention Type
Device
Intervention Name(s)
EsoGuard
Intervention Description
EsoGuard assay (LDT) will be used on cells collected using EsoCheck (510K cleared esophageal cell collection device) and compared to results of EGD plus biopsies (when taken)
Primary Outcome Measure Information:
Title
Primary Efficacy
Description
The sensitivity and specificity of EsoGuard for the diagnosis of BE on samples collected using EsoCheck, wherein the definitive diagnosis of BE is made by concomitant EGD and biopsy.
Time Frame
Cross-sectional point in time per subject through study completion which is up to approximately 5 weeks
Secondary Outcome Measure Information:
Title
Secondary Efficacy
Description
Negative predictive value (NPV) and positive predictive value (PPV), calculated for the observed prevalence and over a range of prevalences from 1 to 15%.
Time Frame
Cross-sectional point in time per subject through study completion which is up to approximately 5 weeks
Other Pre-specified Outcome Measures:
Title
Safety of EsoCheck device administration
Description
Assessed by evaluation of AEs/SAEs/ADEs/SADEs/USADEs and Medical Device Deficiency Incidents
Time Frame
Cross-sectional point in time per subject through study completion which is up to approximately 5 weeks

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Men aged 50 years old and older ≥5 years either of GERD symptoms, GERD treated with proton pump inhibitor (PPI) therapy (whether symptom control is achieved or not), or, any combination of treated and untreated periods, as long the cumulative total is at least 5 years No solid foods eaten for at least 2 hours prior to EsoCheck procedure One or more of the following risk factors: Caucasian race Current or past history of cigarette smoking BMI of at least 30 kg/m2 First-degree relative with BE or EAC - Exclusion Criteria: History of prior EGD procedure Inability to provide written informed consent On anti-coagulant drug(s) that cannot be temporarily discontinued Known history of esophageal varices or esophageal stricture Any contraindication, as deemed in Investigator's medical judgment, to undergoing the EsoCheck procedure, undergoing the EGD procedure, and/or having biopsies taken, including but not limited to due to comorbidities such as coagulopathy or a known history of esophageal diverticula, esophageal fistula and/or esophageal ulceration History of difficulty swallowing (dysphagia) or painful swallowing (odynophagia), including swallowing pills Oropharyngeal tumor History of esophageal or gastric surgery, with exception of uncomplicated surgical fundoplication procedure History of myocardial infarction or cerebrovascular accident within past 6 months History of esophageal motility disorder Currently implanted Linx device
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michelle McDermott
Organizational Affiliation
Lucid Diagnostics
Official's Role
Study Director
Facility Information:
Facility Name
Lucid Investigative Site
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Facility Name
Lucid Investigative Site
City
Englewood
State/Province
Colorado
ZIP/Postal Code
80113
Country
United States
Facility Name
Lucid Investigative Site
City
Naples
State/Province
Florida
ZIP/Postal Code
34102
Country
United States
Facility Name
Lucid Investigative Site
City
Palm Harbor
State/Province
Florida
ZIP/Postal Code
34684
Country
United States
Facility Name
Lucid Investigative Site
City
Macon
State/Province
Georgia
ZIP/Postal Code
31201
Country
United States
Facility Name
Lucid Investigative Site
City
Idaho Falls
State/Province
Idaho
ZIP/Postal Code
83404
Country
United States
Facility Name
Lucid Investigative Site
City
Rockford
State/Province
Illinois
ZIP/Postal Code
61107
Country
United States
Facility Name
Lucid Investigative Site
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70112
Country
United States
Facility Name
Lucid Investigative Site
City
Shreveport
State/Province
Louisiana
ZIP/Postal Code
71105
Country
United States
Facility Name
Lucid Investigative Site
City
Wyoming
State/Province
Michigan
ZIP/Postal Code
49519
Country
United States
Facility Name
Lucid Investigative Site
City
Flowood
State/Province
Mississippi
ZIP/Postal Code
39232
Country
United States
Facility Name
Lucid Investigative Site
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68124
Country
United States
Facility Name
Lucid Investigative Site
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Facility Name
Lucid Investigative Site
City
Rochester
State/Province
New York
ZIP/Postal Code
14620
Country
United States
Facility Name
Lucid Investigative Site
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27599
Country
United States
Facility Name
Lucid Investigative Site
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73102
Country
United States
Facility Name
Lucid Investigative Site
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Facility Name
Lucid Investigative Site
City
Greenville
State/Province
South Carolina
ZIP/Postal Code
29615
Country
United States
Facility Name
Lucid Investigative Site
City
Knoxville
State/Province
Tennessee
ZIP/Postal Code
37909
Country
United States
Facility Name
Lucid Investigative Site
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37212
Country
United States
Facility Name
Lucid Investigative Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Lucid Investigative Site
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84132
Country
United States
Facility Name
Lucid Investigative Site
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23249
Country
United States
Facility Name
Lucid Investigative Site
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23298
Country
United States
Facility Name
Lucid Investigative Site
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Facility Name
Lucid Investigative Site
City
Valladolid
ZIP/Postal Code
47012
Country
Spain
Facility Name
Lucid Investigative Site
City
Zaragoza
ZIP/Postal Code
50009
Country
Spain

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE

We'll reach out to this number within 24 hrs